Industry Analysis & Industry Trends
On the mend
The Anti-Fungal Medication OTC industry managed to perform well during the recession, as lower rates of insurance spurred demand for less-expensive treatments. Further, demand from consumers who self-diagnosed themselves has benefited the industry, since individuals often purchase products that they do not need. Revenue will continue to grow, despite higher rates of insurance, as the population ages and firms invest in R&D.... purchase to read more
Industry Report - Industry Key Buyers Chapter
The top four companies are expected to generate 16.6% of industry revenue in 2011. This percentage is a sharp decline from 2006, when Novartis alone held a 39.5% market share. However, its patent for Lamasil expired in 2007, when direct competition from generic brands entered into US and foreign markets. The sharp decline in revenue as a result of the patent expiration has driven down market share concentration from medium to low during the past five years.
Product innovation has caused a further decline in market share during the past five years. Generic brands have introduced new variations of applicators and packaging. Other companies gained market share because consumers had more choices in products... purchase to read more